鄭熙錫

  • 资深外国律师
  • T. +82-2-3404-0247
  • F. +82-2-3404-7307
  • E. heesug.chung@bkl.co.kr

介绍

Heesug Chung is a senior foreign attorney in the Finance and Capital Markets Practice Group at Bae, Kim & Lee LLC. Mr. Chung's practice covers a broad range of financing and capital markets matters, including corporate financing, overseas investment, foreign-direct investment, acquisition finance, project finance, private equity investment and M&A.

Prior to joining BKL, Mr. Chung worked in the Capital Markets Team at the Hong Kong office of Clifford Chance, where he had advised on some of the largest and most complex capital markets and finance transactions, including IPOs in various jurisdictions such as Hong Kong, Singapore, Malaysia and Korea. After joining BKL, Mr. Chung specializes in capital markets and finance transactions. Particularly in regard to IPO transactions, Mr. Chung advised on large-scale high-profile Korea Exchange listings with international tranches by Korean companies, such as SK Biopharm, Big Hit Entertainment, Samsung Biologics, Doosan Bobcat and Cheil Industries, not to mention complex Korea Exchange listings by foreign companies, such as US companies Psomagen and Englewood Lab, and China-based companies Organic Tea Cosmetics and Great Rich Technologies. In addition, Mr. Chung also advised on major cross-border capital markets transactions by Korean conglomerates, financial institutions, government/quasi-government organizations, including offerings and listings of depositary receipts on foreign exchanges, disclosure updates on foreign exchanges and overseas debt securities/convertible bonds offerings. Mr. Chung is fluent in English and Korean, and having majored in Korean Law at Korea University and Securities and Financial Regulation at Georgetown University Law Center, has extensive expertise in international capital markets and finance for foreign and Korean clients.

履历

2014-至今 Bae, Kim & Lee LLC
2009-2013 Clifford Chance LLP, Hong Kong
2008 Committee for Human Rights in North Korea, Washington D.C., USA
2002-2005 Lieutenant, Korean Air Force Operations Command

主要业务案例

Advised on Korean IPOs and Korea Exchange listings by Korean companies: Krafton, KakaoBank, Kakao Pay, K Car, HK inno.N, Big Hit Entertainment, SK Biopharm, Celltrion Healthcare, Doosan Bobcat, Samsung Biologics, Cheil Industries, Innocean, etc.
Advised on Korean IPOs and Korea Exchange listings by foreign companies: NeoImmune Tech, Psomagen, Inc. (US), Englewood Lab, Inc. (US), Great Rich Technologies (Hong Kong), and Organic Tea Cosmetics (Hong Kong)
Advised on listing of depositary receipts representing shares in KRX listed companies: Hanwha Chemical, IBK and OCI
Advised on Korean due diligence for overseas IPOs by foreign companies: Tigermed, K Food Holdings, Zioncom Holdings Limited, Top Dynamic International Holdings, Cowell e-Holdings, etc.
Advised on pre-IPO investments in shares issued by Englewood Lab, Inc. and Access Bio, Inc. (US companies) and CBs issued by Yellowmobile, Inc.
Advised on Korean IPOs and Korea Exchange listings by Korean companies: Krafton, KakaoBank, Kakao Pay, K Car, HK inno.N, Big Hit Entertainment, SK Biopharm, Celltrion Healthcare, Doosan Bobcat, Samsung Biologics, Cheil Industries, Innocean, etc.
Advised on Korean IPOs and Korea Exchange listings by foreign companies: NeoImmune Tech, Psomagen, Inc. (US), Englewood Lab, Inc. (US), Great Rich Technologies (Hong Kong), and Organic Tea Cosmetics (Hong Kong)
Advised on overseas IPO of domestic company: DoubleDown Interactive
Advised on listing of depositary receipts representing shares in KRX listed companies: Hanwha Chemical, IBK and OCI
Advised on Korean due diligence for overseas IPOs by foreign companies: Tigermed, K Food Holdings, Zioncom Holdings Limited, Top Dynamic International Holdings, Cowell e-Holdings, etc.
Advised on pre-IPO investments in shares issued by Englewood Lab, Inc. and Access Bio, Inc. (US companies) and CBs issued by Yellowmobile, Inc.
Advised on post-IPO investments in CBs and shares issued by Englewood Lab, Inc. and Access Bio, Inc. (US companies)
Advised on M&A by Korea Exchange listed foreign companies: Englewood Lab's acquisition of NS Tech, Cosmecca Korea's acquisition of major stake in Englewood Lab
Advised on foreign currency debt securities offerings by Korean or Korea-affiliated issuers: Chinese Yuan denominated foreign exchange equalization bonds by the Republic of Korea, US dollar denominated foreign exchange equalization bonds by the Republic of Korea, US dollar denominated bonds by East-West Power, US dollar denominated secured bonds by Hanwha Chemicals and Hanwha Advanced Materials, Australian dollar denominated secured bonds by Korea Resources Corporation, Japanese Yen denominated bonds by Hanwha Chemicals, Hanwha Energy Corporation Japan and Hyosung, and 18 million Yuan Kimchi bonds by Industrial and Commercial Bank of China
Advised on global MTN program set-ups/updates and takedowns by Korean issuers: Western Power, KDB, KEXIM, Busan Bank, NH Bank, and Water Resources Corporation
Advised on M&As: Tesco's sale of Homeplus, and Applied Materials' acquisition of stake in Sunam
Advised on overseas investments, including alternative investments: Investment in a UK biomass power plant, investment in bonds relating to an Australian coal terminal, and investment in shares of Abu Dhabi University

学历

2008 Georgetown University Law Center (LL.M.)
2002 Korea University (LL.B.)

主要社会活动

奖项
The Legal 500 - Leading Lawyer (2022-2024)
IFLR 1000 - Leading Lawyer (2021-2024)

资格

2009 New York

媒体评价

媒体评价